Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions
Frontiers in Cell and Developmental Biology · 03.06.2024 · 12
DOI: 10.3389/fcell.2024.1416115 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 03.06.2024. Verfasst von Jiaan Lu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical College, Southwest Medical University, Luzhou, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer remains a significant global challenge, with escalating incidence rates and a substantial burden on healthcare systems worldwide. Herein, we present an in-depth exploration of the intricate interplay between cancer cell death pathways and tumor immunity within the tumor microenvironment (TME). We begin by elucidating the epidemiological landscape of cancer, highlighting its pervasive impact on premature mortality and the pronounced burden in regions such as Asia and Africa. Our analysis centers on the pivotal concept of immunogenic cell death (ICD), whereby cancer cells succumbing to specific stimuli undergo a transformation that elicits robust anti-tumor immune responses. We scrutinize the mechanisms underpinning ICD induction, emphasizing the release of damage-associated molecular patterns (DAMPs) and tumor-associated antigens (TAAs) as key triggers for dendritic cell (DC) activation and subsequent T cell priming. Moreover, we explore the contributions of non-apoptotic RCD pathways, including necroptosis, ferroptosis, and pyroptosis, to tumor immunity within the TME. Emerging evidence suggests that these alternative cell death modalities possess immunogenic properties and can synergize with conventional treatments to bolster anti-tumor immune responses. Furthermore, we discuss the therapeutic implications of targeting the TME for cancer treatment, highlighting strategies to harness immunogenic cell death and manipulate non-apoptotic cell death pathways for therapeutic benefit. By elucidating the intricate crosstalk between cancer cell death and immune modulation within the TME, this review aims to pave the way for the development of novel cancer therapies that exploit the interplay between cell death mechanisms and tumor immunity and overcome Challenges in the Development and implementation of Novel Therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Medical College, Southwest Medical University, Luzhou, China.
- Department of Anesthesiology, Southwest Medical University, Luzhou, China.
- Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Department of General Surgery, Dazhou Central Hospital, Dazhou, China.
- Department of Specialty Medicine, Ohio University, Athens, OH, United States.
Zitieren
APA
Lu, J., He, R., Liu, Y., Zhang, J., Xu, H., Zhang, T., Chen, L., Yang, G., Zhang, J., Liu, J., & Chi, H. (2024). Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions. Frontiers in Cell and Developmental Biology, 12. https://doi.org/10.3389/fcell.2024.1416115
Vancouver
Lu J, He R, Liu Y, Zhang J, Xu H, Zhang T, et al. Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions. Frontiers in Cell and Developmental Biology. 2024;12. doi:10.3389/fcell.2024.1416115
BibTeX
@article{Lu2024,
author = {Lu, Jiaan and He, Ru and Liu, Yang and Zhang, Jinghan and Xu, Heng and Zhang, Tianchi and Chen, Li and Yang, Guanhu and Zhang, Jun and Liu, Jie and Chi, Hao},
title = {Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions},
journal = {Frontiers in Cell and Developmental Biology},
year = {2024},
volume = {12},
doi = {10.3389/fcell.2024.1416115}
}
EUVIMED